CEL-SCI Corporation (CVM:NYSEMKT) closed at $1.57 on October 27, 2026, down 1.26% on the day. The stock trades 83.1% below its 52-week high of $9.28 and 76.4% above its 52-week low of $0.890. Over the past year, it lost 82.4%. CEL-SCI Corporation is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
In 252 trading sessions since October 27, 2025, CVM closed higher on 112 days (44%). Its best day was April 6, 2026 (+24.50%) and its worst was May 4, 2026 (-25.88%). The stock moved 10% or more in a single session 32 times.
CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The company's Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.
Find more stocks like CVM with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.